-
公开(公告)号:US20230183250A1
公开(公告)日:2023-06-15
申请号:US18064080
申请日:2022-12-09
申请人: Incyte Corporation
发明人: Joshua Hummel , David M. Burns , Ding-Quan Qian , Xiaozhao Wang
IPC分类号: C07D487/04
CPC分类号: C07D487/04
摘要: The present application provides bicyclic amines of Formula (I):
and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.-
公开(公告)号:US11667635B2
公开(公告)日:2023-06-06
申请号:US17238409
申请日:2021-04-23
申请人: Incyte Corporation
发明人: Liang Lu , Liangxing Wu , Ding-Quan Qian , Wenqing Yao
IPC分类号: C07D471/04
CPC分类号: C07D471/04
摘要: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
-
公开(公告)号:US20220009921A1
公开(公告)日:2022-01-13
申请号:US17238409
申请日:2021-04-23
申请人: Incyte Corporation
发明人: Liang Lu , Liangxing Wu , Ding-Quan Qian , Wenqing Yao
IPC分类号: C07D471/04
摘要: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
-
公开(公告)号:US20210238168A1
公开(公告)日:2021-08-05
申请号:US17229397
申请日:2021-04-13
申请人: Incyte Corporation
发明人: Yun-Long Li , Jincong Zhuo , Ding-Quan Qian , Song Mei , Ganfeng Cao , Yongchun Pan , Qun Li , Zhongjiang Jia
IPC分类号: C07D403/14 , A61P37/06
摘要: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
-
公开(公告)号:US20200377504A1
公开(公告)日:2020-12-03
申请号:US16842558
申请日:2020-04-07
发明人: Liangxing Wu , Colin Zhang , Chunhong He , Yaping Sun , Liang Lu , Ding-Quan Qian , Meizhong Xu , Jincong Zhuo , Wenqing Yao
IPC分类号: C07D471/14 , C07D495/14 , C07D471/20 , C07D498/14 , C07D498/22 , C07D471/22 , C07D491/22 , A61P11/00 , A61P1/16 , A61P19/02
摘要: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
-
公开(公告)号:US10800768B2
公开(公告)日:2020-10-13
申请号:US16373150
申请日:2019-04-02
申请人: Incyte Corporation
发明人: Liangxing Wu , Jingwei Li , Wenqing Yao , Chao Qi , Ding-Quan Qian , Fenglei Zhang
IPC分类号: A61K31/4375 , C07D413/14 , C07D471/04 , A61P37/02 , C07D498/04 , C07D513/04 , C07D487/04 , C07D413/06 , C07D413/12 , A61P37/00
摘要: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
-
公开(公告)号:US10738048B2
公开(公告)日:2020-08-11
申请号:US16239051
申请日:2019-01-03
申请人: Incyte Corporation
发明人: Liang Lu , Liangxing Wu , Ding-Quan Qian , Wenqing Yao
IPC分类号: C07D471/04
摘要: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
-
公开(公告)号:US20200181077A1
公开(公告)日:2020-06-11
申请号:US16689444
申请日:2019-11-20
申请人: Incyte Corporation
发明人: Liangxing Wu , Chunhong He , Ding-Quan Qian , Bo Shen , Wenqing Yao
IPC分类号: C07D205/04 , C07D401/14 , A61K31/506 , A61K31/497 , A61K31/4427 , A61K31/397 , C12N9/06 , C07D211/34 , C07D403/04 , C07D401/04 , C07D403/14
摘要: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
-
公开(公告)号:US20200010456A1
公开(公告)日:2020-01-09
申请号:US16555620
申请日:2019-08-29
申请人: Incyte Corporation
发明人: Yun-Long Li , Jincong Zhuo , Ding-Quan Qian , Song Mei , Ganfeng Cao , Yongchun Pan , Qun Li , Zhongjiang Jia
IPC分类号: C07D403/14
摘要: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
-
公开(公告)号:US20190225601A1
公开(公告)日:2019-07-25
申请号:US16373150
申请日:2019-04-02
申请人: Incyte Corporation
发明人: Liangxing Wu , Jingwei Li , Chao Qi , Fenglei Zhang , Zhenwu Li , Wenyu Zhu , Zhiyong Yu , Kaijiong Xiao , Liang Lu , Song Mei , Ding-Quan Qian , Chunhong He , Yingda Ye , Meizhong Xu , Wenqing Yao
IPC分类号: C07D413/14 , A61K31/4375 , C07D487/04 , C07D513/04 , C07D498/04 , C07D413/06 , C07D471/04 , A61P37/00 , C07D413/12 , A61P37/02
摘要: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
-
-
-
-
-
-
-
-
-